+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis



The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis



Journal of Bone and Mineral Metabolism 31(2): 206-211



This study was performed to investigate the effects of the co-administration of proton pump inhibitor (PPI) on the efficacy of bisphosphonate (BP) treatment for osteoporosis. A total of 180 women with low bone mineral density were randomly divided into four groups, one in which sodium risedronate was administered with sodium rabeprazole and one in which only risedronate was administered (BP + PPI and BP groups, respectively). The biomarkers were measured at the baseline and every 3 months, inlcuding: N-terminal telopeptide of type I collagen corrected for creatinine, bone-specific alkaline phosphatase (BAP), parathyroid hormone, bone mineral density (BMD) of the lumbar spine and physical parameters evaluated according to the SF-36v2™ Health Survey. Statistical comparisons of these parameters were performed after 9 months. Data were available for a total of 137 patients (62 in the BP group and 75 in the BP + PPI group). The Δ % value of increase in BMD and improvement of physical functioning in the BP + PPI group were significantly larger, and its decrease in BAP in the BP + PPI group was significantly smaller than that in the BP group. It is expected that risedronate administration in combination with a PPI may be more effective not only for treating osteoporosis but also improving physical fitness than treatment with risedronate alone.

(PDF emailed within 0-6 h: $19.90)

Accession: 036678539

Download citation: RISBibTeXText

PMID: 23138352

DOI: 10.1007/s00774-012-0406-9


Related references

The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. Journal of Osteoporosis 2014: 607145, 2014

Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in the treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine 93(12): E64, 2014

Comparison of concurrent treatment with vitamin K 2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. Journal of Bone and Mineral Metabolism 35(4): 385-395, 2016

Retraction. Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine 93(29): 399-399, 2015

Proton pump inhibitor - side effects and complications of long-term proton pump inhibitor administration. Zeitschrift für Gastroenterologie 55(1): 63-74, 2017

Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. Journal of Gastroenterology and Hepatology 33(3): 623-630, 2017

Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis. Biological and Pharmaceutical Bulletin 35(7): 1159-1165, 2012

Acid-related diseases. What is the current rescue treatment of choice for Helicobacter pylori: quadruple therapy (proton pump inhibitor, bismuth, tetracycline and metronidazole) or triple therapy with proton pump inhibitor, amoxicillin and levofloxacin?. Gastroenterologia Y Hepatologia 31(6): 400-401, 2008

Is oral combination therapy with a proton-pump inhibitor and H2 receptor antagonist effective as initial treatment?. Journal of Gastroenterology 42(6): 510-511, 2007

The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study. Bone 81: 675-682, 2016

The cost-effectiveness of intravenous proton pump inhibitor continuous infusion administered prior to endoscopy in the treatment of patients with non-variceal upper GI bleeding. Gastroenterology 122(4 Suppl 1): A 682, 2002

Treatment for resilient cough owing to laryngopharyngeal reflux with a combination of proton pump inhibitor and Gaviscon® Advance: how we do it. Clinical Otolaryngology 36(6): 583-587, 2012

Proton pump inhibitor therapy and osteoporosis. Current Drug Safety 3(3): 204-209, 2008

Proton Pump Inhibitor Therapy and Osteoporosis. Current Drug Safety 3(3): 204-209, 2008

Effects of Proton Pump Inhibitor Administration and Intake of a Combination of Yogurt and Galactooligosaccharides on Bone and Mineral Metabolism in Rats. Nutrients 8(10), 2016